Entities / Company
Haemonetics.
company based in Braintree, Massachusetts, USA
- Reports this week
- 0
- Active events
- 0
- Connections
- 47
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Haemonetics CEO Chris Simon reflected on the company's performance on August 8, 2026.Some support2 reports
-
Haemonetics announced that it funded a study being conducted at Emory University.Some support1 report
-
Bank of America and Mizuho issued rating changes and price targets for Haemonetics on August 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Jin Medical International and Haemonetics are medical companies competing in the market, with Jin Medical International based in Changzhou.Some support1 report
-
Analysts compared the business models and market performance of Haemonetics and Curaleaf.Some support1 report
-
Citi initiated positive catalyst watch on Haemonetics and GE Healthcare in the MedTech sector.Some support2 reports1 development inside
-
Rothschild advises buying when there is blood on the streets regarding Haemonetics.Speculative1 report
-
Financial analysts, including Needham & Company, Mizuho Financial Group, and Marie Thibault, questioned Haemonetics' long-term growth and product performance.Speculative1 report
-
Wolfe initiated coverage on July 9, 2025, giving an Outperform rating, noting that both Better and Haemonetics benefit from the AI deployment secular shift.Speculative1 report
-
UnitedHealth Group, ICU Medical, and Haemonetics integrated their supply chains with Canada for pharmaceuticals and medical devices.Some support1 report
-
Integer and Bausch + Lomb are identified as companies operating in the medical devices & supplies segment.Some support2 reports
-
Haemonetics is based in Braintree, Massachusetts.Some support2 reports
-
Zacks Investment Research published stock analysis reports concerning Haemonetics on August 7, 2025.Some support1 report
-
Haemonetics was classified into the Zacks Medical - Products industry as of August 7, 2025.Some support1 report
-
Haemonetics reported financial results for August 2025, noting that the rest of Asia contributed 6.7% of its total revenue.Some support1 report
-
Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Haemonetics this week
News at the entities that move Haemonetics most-
Citigroup Mentioned togetherCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Haemonetics
-
Bank of America Mentioned togetherGoldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Moves Haemonetics
-
Curaleaf Mentioned togetherBoth Delcath Systems and Curaleaf are facing market scrutiny as healthcare companies.Moves Haemonetics
-
Manufacturers Life Insurance Company TransactionalManufacturers Life Insurance Company purchased a new stake in Telos shares, a company serving customers in the United States.Moves Haemonetics
-
Boston Shared contextThe Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Moves Haemonetics
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Haemonetics
Connections
The 13 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Christopher Simon Structural
Christopher Simon serves as the CEO of Haemonetics, guiding its core product focus and platforms.
-
Chris Simon Structural
Chris Simon serves as the President and CEO of Haemonetics.
-
Emory University Transactional
Haemonetics provided financial support for a study being conducted at Emory University.
-
Plasma Operational
The plasma market segment drives the financial performance and revenue results of Haemonetics.
-
Chris Simon Structural
Chris Simon serves as the CEO of Haemonetics, providing executive leadership and direction for the company.
-
Citigroup Mentioned together
Citigroup provided a buy rating on Haemonetics.
-
Bank of America Mentioned together
Bank of America provided a stock rating and price target for Haemonetics.
-
Curaleaf Mentioned together
Analysts compared the business models and market performance of Haemonetics and Curaleaf.
Show all 13 connections
-
Mizuho Mentioned together
Mizuho assessed Haemonetics by raising its price target and giving an outperform rating.
-
Manufacturers Life Insurance Company Transactional
A single snapshot indicates a transactional event involving the purchase of company shares between the two entities.
-
Boston Shared context
Haemonetics is located in the Boston metropolitan area.
-
MarketBeat Mentioned together
No evidence found in the provided timeline to establish a relationship between MarketBeat and Haemonetics.
-
Persona Mentioned together
No evidence of a relationship between Persona and Haemonetics was found in the provided timeline.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 eventsJune 2026
13 events- Jin Medical International and Haemonetics are medical companies competing in the market, with Jin Medical International based in Changzhou.
- Analysts compared the business models and market performance of Haemonetics and Curaleaf.
- Citi initiated positive catalyst watch on Haemonetics and GE Healthcare in the MedTech sector.
- Rothschild advises buying when there is blood on the streets regarding Haemonetics.
- Financial analysts, including Needham & Company, Mizuho Financial Group, and Marie Thibault, questioned Haemonetics' long-term growth and product performance.
- Wolfe initiated coverage on July 9, 2025, giving an Outperform rating, noting that both Better and Haemonetics benefit from the AI deployment secular shift.
- UnitedHealth Group, ICU Medical, and Haemonetics integrated their supply chains with Canada for pharmaceuticals and medical devices.
- Integer and Bausch + Lomb are identified as companies operating in the medical devices & supplies segment.
- Haemonetics is based in Braintree, Massachusetts.
- Zacks Investment Research published stock analysis reports concerning Haemonetics on August 7, 2025.
- Haemonetics was classified into the Zacks Medical - Products industry as of August 7, 2025.
- Haemonetics reported financial results for August 2025, noting that the rest of Asia contributed 6.7% of its total revenue.
- Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.